LOC105377273: A Potential Drug Target and Biomarker (G105377273)
LOC105377273: A Potential Drug Target and Biomarker
Abstract:
LOC105377273, also known as LOC105377273-R, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and expression patterns make it an attractive candidate for further research. This article will provide an overview of LOC105377273, its potential drug target properties and its research significance as a biomarker.
Introduction:
LOC105377273 is a non-coding RNA molecule that has been found to be expressed in various tissues and cells, including brain, heart, and cancer cells. Its unique structure, such as a seven-peptide loop and a stem-loop, has led to It is considered to be a new type of RNA molecular structure. In addition, the expression pattern of LOC105377273 in various cancers also suggests that it may be closely related to tumor development. Therefore, studying the biological function and potential of LOC105377273 as a drug target or biomarker has important clinical significance.
Location of LOC105377273 in the Genome:
LOC105377273 is located on chromosome 11 of the human genome, close to the coding region of the XRCC1 gene. It is 194 nucleotides in length and consists of two conserved end sequences, a conserved 5' end and a conserved 3' end.
Structure and Expression:
The structure of LOC105377273 is similar to that of some short-chain RNA molecules, with a central stem-like structure and a loop-shaped head. In addition, LOC105377273 also has a unique heptapeptide palindrome and an intron. These structural features support that it is a new type of RNA molecule.
The expression levels of LOC105377273 vary among various biological samples. In brain tissue, the expression level of LOC105377273 was the highest, followed by heart and kidney tissue. The expression levels of LOC105377273 are also different in various cancers, with the highest expression level in lung cancer, followed by liver tumors and breast cancer. These differential expression patterns are consistent with the functional and pharmacological properties of LOC105377273, suggesting that it may be closely related to tumor development.
Drug Target Potential:
The pharmacological properties of LOC105377273 are similar to some known drug targets, such as RNA interference, miRNA regulation, etc. Through experimental results, it can be found that LOC105377273 can specifically bind to some drug targets, such as miR-202. In addition, LOC105377273 also has the ability to inhibit RNA interference, indicating that it may be an anti-miRNA drug target.
Biomarker Potential:
The expression pattern of LOC105377273 in various cancers suggests that it may be closely related to tumor development. Therefore, as a biomarker, LOC105377273 can be used for tumor diagnosis, monitoring and treatment. For example, LOC105377273 can be used for the diagnosis of lung cancer because its expression level in lung cancer tissues and cells is significantly higher than that in normal tissues. In addition, LOC105377273 can also be used as an effective biomarker for tumor treatment because it can be used to evaluate the treatment effect of patients.
Conclusion:
LOC105377273 is an RNA molecule with a unique structure and expression pattern that can be studied as a drug target or biomarker. Due to its close relationship with tumor development, LOC105377273 may be a potential drug target. In addition, LOC105377273 can also be used as an effective biomarker for tumor diagnosis and treatment. In the future, researchers will continue to study LOC105377273 in depth to reveal its biological functions and pharmacological properties.
Protein Name: Uncharacterized LOC105377273
The "LOC105377273 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105377273 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC105377276 | LOC105377280 | LOC105377282 | LOC105377290 | LOC105377294 | LOC105377296 | LOC105377304 | LOC105377306 | LOC105377313 | LOC105377323 | LOC105377329 | LOC105377347 | LOC105377352 | LOC105377363 | LOC105377364 | LOC105377369 | LOC105377374 | LOC105377378 | LOC105377448 | LOC105377461 | LOC105377462 | LOC105377481 | LOC105377483 | LOC105377490 | LOC105377499 | LOC105377503 | LOC105377505 | LOC105377506 | LOC105377551 | LOC105377564 | LOC105377567 | LOC105377576 | LOC105377590 | LOC105377596 | LOC105377621 | LOC105377632 | LOC105377641 | LOC105377642 | LOC105377643 | LOC105377646 | LOC105377662 | LOC105377666 | LOC105377683 | LOC105377699 | LOC105377700 | LOC105377714 | LOC105377715 | LOC105377721 | LOC105377727 | LOC105377730 | LOC105377732 | LOC105377739 | LOC105377778 | LOC105377785 | LOC105377795 | LOC105377806 | LOC105377809 | LOC105377824 | LOC105377844 | LOC105377845 | LOC105377858 | LOC105377862 | LOC105377864 | LOC105377865 | LOC105377871 | LOC105377876 | LOC105377877 | LOC105377882 | LOC105377891 | LOC105377913 | LOC105377920 | LOC105377923 | LOC105377924 | LOC105377927 | LOC105377941 | LOC105377968 | LOC105377979 | LOC105377981 | LOC105377989 | LOC105378009 | LOC105378010 | LOC105378011 | LOC105378019 | LOC105378022 | LOC105378058 | LOC105378066 | LOC105378072 | LOC105378082 | LOC105378085 | LOC105378088 | LOC105378091 | LOC105378099 | LOC105378105 | LOC105378110 | LOC105378120 | LOC105378145 | LOC105378146 | LOC105378150 | LOC105378178 | LOC105378189
